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ABSTRACT
Over recent years small submicroscopic DNA copy-
number variants (CNVs) have been highlighted as an
important source of variation in the human genome,
human phenotypic diversity and disease suscep-
tibility. Consequently, there is a pressing need for
the development of methods that allow the efficient,
accurate and cheap measurement of genomic copy
number polymorphisms in clinical cohorts. We have
developed a simple competitive PCR based method
to determine DNA copy number which uses the
entire genome of a single chimpanzee as a compet-
itor thus eliminating the requirement for competitive
sequences to be synthesized for each assay. This
results in the requirement for only a single reference
sample for all assays and dramatically increases
the potential for large numbers of loci to be ana-
lysed in multiplex. In this study we establish proof
of concept by accurately detecting previously char-
acterized mutations at the PARK2 locus and then
demonstrating the potential of quantitative inter-
species competitive PCR (qicPCR) to accurately
genotype CNVs in association studies by analysing
chromosome 22q11 deletions in a sample of pre-
viously characterized patients and normal controls.
INTRODUCTION
It is well recognized that rare large microscopic genomic
abnormalities are associated with disease (1,2). Over
recent years a number of landmark studies have shown
that smaller submicroscopic DNA copy-number variants
(CNVs) (typically segments >1kb that are deleted, dupli-
cated or inserted) are an important source of variation in
the human genome (3). That CNVs are a common source
of genetic variation in healthy individuals (4–7) implies
that some result in no obvious phenotypic changes.
However, as CNVs can disrupt entire genes and regulatory
regions (4,6,8,9) an increasing number have been shown to
make an important contribution to human phenotypic
diversity and play a role in disease susceptibility (10–13).
Consequently, the identiﬁcation of disease-related CNVs
is important both clinically and for studies aiming to iden-
tify disease-related aetiological pathways. A key step in
the investigation of CNVs will involve the analysis of spe-
ciﬁc loci in disease association studies and to achieve this,
CNVs will have to be accurately typed in large clinical
cohorts.
Array-based methodologies (14) have allowed large
numbers of CNVs to be detected and characterized.
Such methods have however been developed mainly for
studies aimed at accurately detecting CNVs and in order
to maintain a low false positive detection rate typically set
stringent inclusion criteria which can often result in an
inﬂated false negative rate (15). Therefore, it is generally
accepted that a conﬁrmatory analysis using an indepen-
dent method is required to accurately determine the fre-
quency CNVs identiﬁed by array-based methods.
Association studies require an extremely accurate deter-
mination of the genotype at each locus for large numbers
of samples. To perform association analysis on CNVs it is
essential that all levels of copy number are accurately
determined in each sample (0, 1, 2, 3, etc.). Estimations
of DNA copy number from data generated by array-based
studies often does not fall into discrete categories and
instead can typically form a continuous distribution. In
fact, a recent assessment of 1500 CNVs identiﬁed by
array-based discovery studies revealed that the call data
of only 70 were of the standard expected of genotyping
assays (15). This problem is likely to be an even greater
issue for smaller CNVs, which contain lower numbers of
probes. It is well recognized that even relatively small
error rates can dramatically reduce the power of an asso-
ciation study (16), therefore, inaccurate estimates of copy
number are unacceptable and inﬂuence both type I and
type II error. To address this, some have attempted to ﬁt
such data into the appropriate discrete categories (7,17),
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are likely to be more amenable to some CNVs than others.
Given this, a more satisfactory approach would be to
develop assays that estimate DNA copy number with suf-
ﬁciently high quality that artefacts introduced by experi-
mental noise are suitably reduced. Such approaches would
also facilitate the economic association analysis of CNVs
in large replication samples. As a result of these issues, the
development of methods that allow eﬃcient, accurate and
cheap measurement of genomic copy number polymor-
phisms in clinical cohorts has been recently recognized
as one of the most pressing needs in CNV research (15,19).
A number of methods exist that allow accurate quanti-
tation of DNA copy number (20–25), however, none are
particularly well suited to large-scale association analysis,
either because the assay requires intensive optimization or
because the analysis platform on which they have been
developed is not best applied to high throughput studies.
Competitive PCR is an established technique that involves
amplifying a test DNA sequence in the presence of a com-
petitor sequence, which is identical apart from a single
nucleotide, which allows both sequences to be distin-
guished. Given a known concentration of the competitor,
the test sequence can be accurately quantiﬁed. Typically,
the source of the competitor is a synthetic DNA sequence,
however, the requirement for a competitor to be syn-
thesized to match each test locus is often impractical for
studies analysing large numbers of loci. To avoid this,
others have shown that very accurate estimates of DNA
copy number can be obtained by amplifying the test locus
in the presence of a paralogous locus of known copy
number (25). However, not all test loci will have a non-
deleted/duplicated paralogous sequence, limiting the
number of assays that can be analysed by this approach.
We have applied competitive PCR to determine DNA
copy number by exploiting the high degree of conserva-
tion between orthologous human and chimpanzee geno-
mic sequence. To achieve this we have co-ampliﬁed
orthologous loci and targeted non-conserved nucleotides
by primer extension to distinguish between template from
the two species (Figure 1). Quantitative interspecies
qicPCR uses the entire genome of a single chimpanzee
as a competitor. This results in the requirement for only
a single competitor sample for all assays and dramatically
increasing the potential of large numbers of loci to be
analysed in multiplex. As the rate of ﬁxed (non-poly-
morphic) interspecies sequence divergence is  1% (26)
then >3 10
7 single nucleotides could potentially be tar-
geted. Therefore, qicPCR can potentially be used to ana-
lyse the majority of CNVs. These factors, together with
accuracy, low cost and potential application to array plat-
forms make it potentially amenable to studies performing
multiplex high throughput association analysis of CNVs.
Here, we establish proof of concept by ﬁrst accurately
Figure 1. Schematic representation of the principle of quantitative interspecies competitive PCR. Human and P. troglodytes speciﬁc alleles are
represented by alleles ‘C’ and ‘G’, respectively.
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PARK2 locus and then demonstrating the potential of
qicPCR to analyse CNVs in association studies by geno-
typing chromosome 22q11 deletions in a sample of pre-
viously characterized patients and normal controls.
METHODS
Samples
All subjects were unrelated and provided written informed
consent to participate in genetic studies.
Parkinsons disease (PD) samples. Our initial analysis was
based on two patients diagnosed with PD who had been
previously characterized as carrying PARK2 mutations;
patient PD-patient1 was hemizygously deleted at exon 3
while patient PD-patient2 carried a heterozygous duplica-
tion of exon 6. All mutations were molecularly conﬁrmed
by MLPA.
22q11DS samples. We analysed 20 unrelated individuals
who carried hemizygous deletions at 22q11 as determined
by ﬂuorescence in situ hybridization using the N25 probe
(Oncor Inc., Gaithersburg, MD, USA).
Control samples. All 733 unrelated individuals had been
collected for use as controls, details of which have been
previously described (27). The 10 samples used as controls
against the PD patients had previously not been screened
for the PARK2 mutations, however, given the rarity of
such pathogenic mutations it is unlikely that they were
carriers. All samples had however been previously
excluded for the presence of typical 22q11 deletions
region (28).
Chimpanzee. Pan troglodytes DNA was obtained from the
cell line EB176 (JC) deposited at ECACC (http://www.
ecacc.org.uk/).
Molecular assays
MLPA assay. Samples were analysed using the SALSA
P051/P052 Parkinson MLPA probe kit (MRC Holland,
Amsterdam, The Netherlands) following manufacturer’s
instruction. Each kit contains a probe for exons 1 to 12
of the PARK2 gene. All steps were performed on the same
MJ thermocycler. Brieﬂy, 100ng of DNA was denatured
at 988C and hybridized to the probes by incubation
(16–17h, 608C) with 1.5ml SALSA probemix and 1.5ml
of MLPA buﬀer. The ligation reaction was carried out
by incubating the 8ml of hybridized product and 32mlo f
Ligase-65 mix for 15min at 548C, followed by 5min at
988C. The PCR was performed in a 50ml reaction using
10ml of ligation product, 4mlo f1 0 SALSA PCR buﬀer
and 10ml of Polymerase mix. The PCR cycling conditions
were 608C hotstart, followed by 35 cycles of 958C for 30s,
608C for 30s and 728C for 60s, followed by 728C for
20min. The PCR product was analysed on an ABI 3100
Sequencer (Applied Biosystems, Foster City, CA, USA)
with a GeneScan500 Rox internal size standard.
qicPCR assays
PCR. PCR was performed on MJ thermocyclers in a 5ml
reaction using approximately 12ng of dried-down geno-
mic human DNA (hsDNA), 12ng of P. troglodytes DNA
(ptDNA), 0.5pmol of each primer in multiplex, 250mM
dNTPs, 0.325mlo f1 0  20mM MgCl PCR Buﬀer and
0.1units of Hotstar Taq polymerase (Qiagen, Valencia,
CA, USA). The PCR cycling parameters were 958C for
15min, followed by 45 cycles of 948C for 20s, 568C for
30s and 728C for 1min, followed by 728C for 3min.
Primer extension. Primer extension was performed on MJ
thermocyclers in 9ml reactions using the 7ml SAP-treated
PCR product, 6.6–13.3 pmol of each primer in multiplex,
0.25ml of iplex buﬀer, 0.25ml of iplex termination mix and
0.05ml of iplex enzyme (Sequenom, San Diego, CA, USA).
The cycling parameters were 948C for 30s, followed by
40 cycles of 948C for 5s and a nested 5 cycles of 528C
for 5s and 808C for 5s, followed by 728C for 3min.
qicPCR assay selection. Interspecies sequence diﬀerences
were identiﬁed by aligning the respective genomic DNA
sequences of human (homo sapiens) and chimpanzee
(P. troglodytes) using UCSC Blat (http://genome.ucsc.
edu/). Nucleotides that diﬀered between human and
chimp were identiﬁed and with reference to the UCSC
genome browser human March 2006 build and the chim-
panzee genome database at the Broad Institute (http://
www.broad.mit.edu/ftp/pub/assemblies/mammals/chimp_
SNPs/), known human and chimpanzee SNPs were
excluded. Single nucleotide extension assays were then
designed to target the non-conserved nucleotides using
Sequenom Assay Design v3.1 software.
To study the mutations in the PD patients the human
reference sequence at the PARK2 locus (NCBI build 36.1,
chr6:161,689,662-162,784,495) with its orthologous
sequence in P. troglodytes (genome build 2 version 1,
chr6:164,335,097-165,462,200). To study the deletion at
22q11 we aligned the human genome NCBI build 36.1,
chr22:18131905-18,222,087 with its orthologous region in
P. troglodytes (genome build 2 version 1, chr22:18221742-
18316567). Primer extension assays (Sequenom iplex
TM,
San Diego, CA, USA) were then designed to target nucleo-
tides that were not conserved between the two species at
the PARK2 locus (20 assays) and at 22q11 (10 assays)
(Supplementary Table 1). Internal control assays were
designed by identifying nucleotides that were not con-
served between human and chimpanzee at a number of
autosomal regions that had showed no previous evidence
for harbouring common CNVs (Supplementary Table 2).
qicPCR assays targeting the PARK2 locus were designed
as two independent multiplex reactions each containing
9 and 11 independent test assays as well as a single refer-
ence assay. qicPCR assays targeting 22q11 were designed
as two independent multiplex reactions each containing
ﬁve 22q11 test assays and ﬁve reference assays.
Standard curve. The genomic DNA from a single human
reference sample was quantiﬁed to 32ng/ul by pico green
analysis and then serially diluted to 16, 8, 4, 2 and 1ng/ul.
For each titrate, PCR followed by primer extension was
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(4ng/ul) as per the manufacturer’s instructions with the
iplex chemistry. The peak areas of the extended primers
speciﬁc to the respective human and chimpanzee alleles
were determined following analysis on a Sequenom
MassARRAY
TM system. The amount of hsDNA relative
to that of ptDNA at each locus (hsDNA
relative) was then
estimated by
hsDNA
relative ¼
hs peak height
ðhs peak height þ pt peak heightÞ
A reference standard curve was generated by plotting
hsDNA
relative (x-axis) against the log of known hsDNA
concentration (y-axis) and from this the slope and inter-
cept was estimated from the equation of the straight line,
y=mx+c. This simple and rapid procedure was per-
formed for each primer extension assay.
qicPCR analysis. For each test sample, the assay was per-
formed using equal concentrations of genomic hsDNA
and ptDNA (3ul of each at  4ng/ul) as described earlier.
The area under peaks corresponding to extended primer
peaks of the respective human and chimpanzee nucleo-
tides (Figure 1) was then determined and the data were
used to estimate hsDNA
relative for each primer extension
assay. With reference to the respective standard curve, the
quantity of hsDNA present in each primer extension assay
(hsDNA
quant) was then estimated by
hsDNA
quant ¼ EXP½ðhsDNA
relative   mÞþc 
where m and c were derived from the reference standard
curve.
The estimated hsDNA copy number at the test locus
was determined as the ratio of hsDNA
quant determined
at the test and internal control loci, respectively: a ratio
of 1:1 being expected in the absence of a CNV, 0.5 for a
heterozygous deletion, 1.5 for a heterozygous duplication.
Dividing each ratio by 0.5 provided an estimate of the
human DNA copy number at the test locus (hsCN).
When multiple test assays from the same locus were
used we ﬁrst determined the average hsDNA
quant at the
test locus and then estimated the average hsDNA copy
number by calculating the ratio to the hsDNA
quant deter-
mined at each independent reference assay.
Silhouette scores. Silhouette scores are a graphical aid for
interpretation and validation of data clusters that provides
a measure of how well a data point was classiﬁed when it
was assigned to a cluster (29). In brief, they are determined
by comparing the distance between each data point within
a cluster to the distance between each data point in any
other cluster. The overall average silhouette score was
calculated for each qicPCR assay using the software
ClusterA (29).
RESULTS AND DISCUSSION
Evaluation of qicPCR
To initially evaluate qicPCR we analysed a total of 11
probes designed to assay exons at the PARK2 locus and
compared the results to data generated by the established
technique of MPLA (23). The standard curves of each
qicPCR assay being presented in Supplementary
Table 3. All probes were analysed in 10 healthy controls
as well as two PD individuals who had previously been
characterized to carry PARK2 mutations. Analysis of the
human DNA copy number (hsCN) determined for the
assays targeting PARK2 exons 3 and 6 established that
qicPCR was capable of detecting both the heterozygous
deletion at exon 3 (mean hsCN=1.08) and the heterozy-
gous duplication at exon 6 (mean hsCN=2.88) in the
respective PD samples (Table 1). Neither assay detected
Table 1. Copy number estimates at the PARK2 locus
ID Test PARK2 assays
Exon 3a Exon 3b Exon 4b Exon 5a Exon 5b Exon 6a Exon 8a Exon 8b Exon 9b Exon 10a Exon 11a
05-180 MPLA 1.06 1.06 2.59 2.17 2.17 1.88 2.14 2.14 2.12 2.15 2.27
qicPCR 1.10 1.07 2.07 1.94 2.06 1.91 2 13 2.02 1.93 2.08 1.96
04-115 MPLA 1.96 1.96 1.95 1.71 1.71 2.80 1.86 1.86 1.68 1.86 1.43
qicPCR 2.32 1.84 1.99 1.91 1.96 2.89 2.14 1.79 2.01 2.04 1.88
Control 1 qicPCR 2.05 1.96 1.77 1.85 2 24 2.19 1.92 1.94 1.93 2.07 1.98
Control 2 qicPCR 1.94 1.83 2.00 2.01 2.24 2.31 2.00 2.03 2.01 2.23 2.05
Control 3 qicPCR 1.63 1.60 2.28 1.65 1.99 2 27 1.97 2.08 1.95 1.76 1.93
Control 4 qicPCR 1.91 1.63 2.14 1.88 2.00 2.01 1.90 1.82 1.63 2.05 1.84
Control 5 qicPCR 1.94 1.87 2 14 2.08 1.94 2 22 1.81 1.74 2.16 1.85 2.06
Control 6 qicPCR 2.10 2.01 2.17 1.89 1.91 2.35 2.16 2.12 2.04 2.02 2.07
Control 7 qicPCR 1.71 1.66 2.05 1.63 2.15 1.94 1.68 2.02 1.87 1.70 2.09
Control 8 qicPCR 1.91 1.62 1.90 1.93 2.06 1.98 1.91 2.17 1.94 1.98 2.11
Control 9 qicPCR 1.99 1.73 2.11 1.94 1.96 2.19 1.88 2.19 1.78 2.08 1.77
Control 10 qicPCR 1.94 1.66 2.09 1.79 2 12 2.04 1.87 2.01 1.87 1.88 2.15
All controls Mean 1.91 1.76 2.06 1.86 2.06 2.15 1.91 2.01 1.92 1.96 2.01
SD 0.14 0.15 0.14 0.14 0.12 0.15 0.12 0.14 0.15 0.16 0.12
CV 0.07 0.09 0.08 0.08 0.06 0.07 0.06 0.07 0.08 0.08 0.06
Copy number at PARK2 exons was determined by MLPA and qicPCR in two patients containing previously characterized mutations (highlighted in
grey) and 10 healthy controls. Mean, SD and coeﬃcient of variance were calculated for each qicPCR assay in the 10 control samples only.
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control samples [exon 3a: mean hsCN=1.92 (1.8–2.0);
exon 3b: mean hsCN=1.76 (1.66–1.88); exon 6: mean
hsCN=2.16 (2.04–2.26)], Table 1. Direct comparison of
the hsCN estimates of qicPCR to those generated by
MPLA showed that the results of both methods were
highly correlated, r=0.82, P=0.005 (Table 1 and
Figure 2). No evidence for change in copy number was
observed in either the PD patients or the 10 control sam-
ples at the qicPCR assays that were not targeting PARK2
exons 3 or 6 (mean hsCN=1.98, 95% CI 1.9–2.06),
Table 1.
A total of four replicate experiments were performed for
each sample. Comparison of the average hsCN determined
at each technical replicate indicated that the results of
qicPCR were reproducible (coeﬃcient of variance for sam-
ples with a gain in copy, a loss in copy and also those
showing no evidence of variation being 0.035, 0.09 and
0.01, respectively).
Three PARK2 exons were each assayed using two inde-
pendent probes. Comparison of the hsCN determined for
the 10 control samples revealed that the results for each
pair of probes were consistent: exon 3 [exon 3a: mean
hsCN=0.96 (95% CI 0.90–1.01); exon 3b: mean
hsCN=0.88 (95% CI 0.83–0.94); CV=0.06], exon 5
[exon 5a: mean hsCN=0.93 (95% CI 0.88–0.98); exon
5b: mean hsCN=1.03 (95% CI 0.99–1.07); CV=0.07]
and exon 8 [exon 8a: mean hsCN=0.96 (95% CI 0.91–
1.0); exon 8b: mean hsCN=1.01 (95% CI 0.95–1.06);
CV=0.04], Table 1.
Evaluation of qicPCR in large samples
To be applicable to large-scale association analysis of a
given CNV, qicPCR should allow hsCN at the locus to be
automatically called in >95% of samples with an error
rate <0.1%, which are the typical standards of current
high throughput SNP genotyping platforms (30). It is
therefore essential that the hsCN estimates at each locus
are suﬃciently consistent over large numbers of samples to
allow the clear distinction of those with diﬀerent levels of
copy number.
We used two criteria to assess the quality of the data
generated by qicPCR. First, analysis of the coeﬃcient of
variance of the hsCN estimated for all samples within each
category of copy number known to be present in our
dataset (normal, single copy loss) allowed a speciﬁc assess-
ment of the concordance of the data within each group.
Second, we used silhouette scores (29) to assess the quality
with which the hsDNA estimated by qicPCR formed dis-
tinct clusters. This is eﬀectively a measure of the accuracy
with which data points can be blindly assigned to diﬀerent
groups based on the relative location of all other data
points. Silhouette scores range from  1 to+1 with
assays >0.65 generally being considered high quality,
having minimal distance between the data points within
each group and large distances between groups. We
empirically determined the CV expected of clusters of
data points in a high quality genotyping assay by calculat-
ing the CV for the data generated by 6 independent SNP
genotyping assays (iplex, Sequenom) that we had pre-
viously scored as being high quality (>95% of samples
called with an error rate <0.1%). All had silhouette
scores >0.65 and the CV for all clusters of data points
were <0.1 [mean=0.05 (0.04min 0.07max)]. Based on
this we set our criteria for genotyping quality to be silhou-
ette score >0.65 and CV <0.1.
To assess whether qicPCR was suﬃciently robust to
meet the criteria expected of a genotyping assay we ana-
lysed two independent multiplex panels each consisting of
ﬁve independent test assays designed to detect copy
number variation at chromosome 22q11 (qicPCR22q11a
and qicPCR22q11b). Both multiplex assays were initially
analysed in 10 individuals previously diagnosed with
22q11DS and 10 healthy controls.
In comparison to the preliminary data generated at the
PARK2 locus, analysing a larger number of samples
revealed that while determining the hsDNA copy
number of each 22q11 test probe with comparison to a
single reference probe allowed the 22q11DS samples
[mean hsCN=1.10 (0.58–1.84)] to be generally diﬀeren-
tiated from the non-deleted control subjects [mean
hsCN=2.14 (1.16–3.62)], the quality of the data fell
short of that expected for a genotyping assay [mean sil-
houette score=0.16 ( 0.03 to –0.32); CV of hsCN for
22q11DS samples and non-deleted controls=0.25 and
0.28, respectively].
We reasoned that the measurement error in the hsCN
determined by qicPCR could be reduced by; (1) averaging
multiple independent unlinked reference loci and/or (2)
averaging multiple independent test probes targeting the
same test locus. We therefore set out to systematically
assess the variability associated with these parameters.
Estimating hsCN using a single test probe with reference
to an increasing number of independent control assays
(1 to 5) resulted in tighter conﬁdence intervals for the
average estimated hsCN for both 22q11DS and non-
deleted samples (Figure 3A). However, the modest
reduction in the average CV (22q11DS 0.25–0.19; controls
0.28–0.21) and a minor increase in the silhouette scores
[0.16 ( 0.03min to 0.32max) to 0.32 (0.26min–0.36max)]
(Figure 3A), did not achieve the required performance.
Figure 2. Comparison of the copy number at the PARK2 locus as
determined by MPLA and qicPCR. Copy number estimates of
PARK2 exons 3, 4, 5, 6, 8, 9, 10 and 11 as determined by qicPCR
and MLPA in two patients with previously characterized PARK2
mutations. The assays of exons 3 (A and B) and exon 6, which
detect the deletion and duplication in our test samples PD-patient1
and PD-patient2, respectively, are highlighted.
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assays we considered all 22q11 test probes to be indepen-
dent assays targeting a single CNV (the 22q11 locus).
hsDNAabsolute values were then calculated for each
sample using a single 22q11 test probe and also from the
average of 2, 3, 4 and 5 independent 22q11 test probes.
Estimates of hsCN were then determined with reference to
a single control assay ampliﬁed within the same multiplex
panel. This again revealed that increasing the number of
independent test assays from one to ﬁve resulted in tighter
conﬁdence intervals for the hscopy number for both
22q11DS and non-deleted samples (Figure 3B), but that
the minor reduction in the CV (22q11DS 0.25–0.19; con-
trols 0.28–0.21) and minor improvement in the silhouette
scores [0.16 ( 0.03min to 0.32max) to 0.40 ( 0.02min to
0.65max)] did not the meet the criteria expected for a geno-
typing assay (Figure 3B).
We next assessed the eﬀect of increasing both the
number of independent test probes and also the number
of independent control probes within the same multiplex
reaction. Calculating the hsDNA
quant for the locus as an
average of at least 4 independent test assays and then
determining the mean hsCN for the locus by comparing
to at least 4 reference assays resulted in a considerable
improvement in data quality (Figure 4) where the low
CV <0.09 and high silhouette scores (>0.77) met our pre-
deﬁned criteria for a genotyping assay. We performed an
identical assessment of qicPCR to detect changes in copy
number at 22q11 using an entirely independent multiplex
panel of 22q11 test assays (qicPCR22q11b). Analysis in
the same set of samples revealed that the estimates of
hsCN at 22q11 by each multiplex panel of markers were
similar (Figure 5) and that both CV and silhouette scores
met our predeﬁned criteria when at least 4 independent
test and reference assays were used (data not presented).
Given our experience that the performance of some
assays can be less robust when scaled up, we analysed a
larger series of 753 samples, composed of 733 non-deleted
controls and 20 new 22q11DS samples independent of
those in which the assay was optimized, dispersed
among the control samples. For each sample the hsCN
at the 22q11 locus was determined as an average of ﬁve
locus-speciﬁc test probes and ﬁve reference probes all
located within the same multiplex reaction. All samples
were analysed in duplicate and similar results were
Figure 3. (A) Eﬀect of increasing the number of reference samples to
estimate copy number by qicPCR. (B) Eﬀect of increasing the number
of test assays to estimate copy number by qicPCR. Blue vertical bars
represent the range of hsCN determined by qicPCR for 22q11DS
patients and controls while histograms represent the CV. The ranges
of silhouette scores determined at each parameter are displayed as
black vertical bars. For each measure the mean is indicated as a
small horizontal bar.
Figure 4. Eﬀect of increasing both the number of reference and test
assays to estimate copy number by qicPCR. hsCN was determined at
22q11 for all combinations of 1 to 5 test and reference assays in 10
patients with 22q11DS and 10 non-deleted controls. For simplicity the
CV of only the 22q11DS samples is presented, however, an analogous
pattern was seen in the data for the non-deleted controls.
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22q11DS samples could be clearly distinguished from the
20controlsamples(silhouettescore=0.81)(Figure6).The
mean hsCN estimate of the 22q11DS samples was 0.96
(0.46min 1.48max), mean CV=0.20 (0.14min 0.23max),
while that of the non-deleted controls was 2.07
(1.68min 2.82max), mean CV=0.06 (0.05min 0.07max).
High-throughputgenotypingassaysareexpectedto be suf-
ﬁciently robust to analyse large numbers of samples
(drop-out rate <5%) while maintaining very low geno-
type error rates (<0.1%). Blind genotyping of our sam-
ples using a simple Excel (Microsoft) spreadsheet, which
adhered to a simple semi-automated protocol whereby
samples were called as carrying either 1 or 2 copy num-
bers if the hsCN determined by qicPCR fell with-
in 40% of the expected integer (1 copy=0.6–1.4, 2
copies= 1.6–2.4). Estimates of hsCN that fell outside
these ranges were classed as genotype failures. Analysis
of each single pass experiment resulted in >97% of
samples being genotyped with 100% accuracy (a total
of 46/1506 samples failed to genotype). Moreover, deter-
mining the hsCN as the average of the two experimental
replicates of each multiplex panel further improved the
genotyping quality, with >99.4% of samples genotyped
with 100% accuracy (a total of 5/753 samples analysed in
duplicate failed to be genotyped), suggesting that further
improvements in the quality of quantitative genotyping
of CNVs by qicPCR are possible simply by performing
one replicate experiment.
The accuracy of qicPCR is highly dependent on the
reference locus itself not varying in copy number. While
it is clearly impossible to absolutely eliminate rare CNVs
at any given reference locus, the risk could clearly be
reduced by selecting reference loci from genomic regions
that have previously shown no evidence of common
CNVs. Moreover, this possibility could be further reduced
by designing each multiplex reaction to include multiple
reference loci selected from diﬀerent genomic regions,
allowing rare CNVs present at just one control region to
be detected and excluded from the analysis.
Another potential problem is the presence of SNPs at
the primer-binding sites. Most SNPs are speciﬁc to either
human or chimpanzee (31). Human-speciﬁc SNPs
(hsSNPs) located at the primer-binding sites of either the
test or reference locus would result in polymorphic mis-
matches which could lead to variability in the estimates of
copy number by qicPCR due to allele speciﬁc ‘drop out’.
Consequently, hsSNPs located under the primers of the
test and reference assays would lead to an apparent reduc-
tion and increase of the estimated copy number at the test
locus, respectively. Both test and reference assays should
be excluded for the presence of hsSNPs, the unintentional
selection, which at either the target or reference locus
would likely result in a highly unstable assay. Given that
the qicPCR assay estimates the hscopy number with refer-
ence to only a single chimpanzee genome the presence of
chimpanzee-speciﬁc SNPs (ptSNPs) are likely to have
minimal eﬀect on the accuracy of a qicPCR assay, either
when they have been inadvertently selected as assay tar-
gets or as when they result in mismatches under the primer
sequences. However, qicPCR assays that inadvertently
target ptSNPs will fail if the genotype of the reference
chimpanzee DNA sample is homozygous for the same
nucleotide conserved in human. Ideally ptSNPs should
therefore be avoided, however as the reference chimpanzee
genome sequence was primarily derived from a single
donor (Clint) then this task could be aided by utilizing
the DNA from ‘Clint’ in qicPCR assays.
Single nucleotide substitutions have been estimated to
occur at an average rate of 1.23% between the human and
chimpanzee genome, with  1.06% corresponding to ﬁxed
divergence between the two species (26). Non-conserved
nucleotides are, however, not consistently distributed
throughout the human genome with CpG islands, and
distal regions showing increased rates of divergence (26).
Given this, analyses of the human genome dissected into
1-Mb segments indicate that the rate of divergence with
chimpanzee varies from 0.006 to 0.022 (26), implying that
even in the most conserved regions of the human genome
we could expect non-conserved nucleotides to occur on
Figure 5. Reproducibility of multiplex qicPCR assays. hsCN was deter-
mined at 22q11 using two independent multiplex qicPCR panels in ten
22q11DS patients (blue) and 10 non-deleted controls (red). Each panel
was analysed in triplicate with replicates 1, 2 and 3 for each qicPCR
panel being represented as closed diamonds, crosses and circles,
respectively.
Figure 6. Estimated copy number at 22q11 in 753 samples. Replicate
experiments of a single multiplex qicPCR panel to determine hsCN at
22q11 in twenty 22q11DS patients (blue) and 733 controls (red).
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servative estimate suggests that non-conserved nucleotides
are at least as common as SNPs it is likely that qicPCR
assays could be designed to target a large majority of the
human genome. Clearly, it would be impossible to analyse
human sequences that do not have a chimpanzee homo-
logue by qicPCR, but, comparative analysis of the human
and chimpanzee genomic sequence indicate that this
number is very small, with only 53 genes ( 0.2%) being
identiﬁed as being deleted in either species (26).
The results of large-scale studies aimed at genotyping
CNVs by array methods can be ambiguous, and typically
require validation by an independent assay. As qicPCR
assays target diverged nucleotides then they can act as
an independent assay to validate CNVs detected by
more conventional methods (SNPs, CGH). Moreover,
given the high frequency of ﬁxed non-conserved nucleo-
tides it will be potentially feasible to design qicPCR assays
to analyse small CNVs (<2kb) which are becoming
increasingly the target of CNV studies.
In this study we have shown that qicPCR can accurately
distinguish normal copy number (2 copies) from a single
copy deletion (1 copy) and a single copy gain (3 copies). A
number of reports of disease association have involved
more complex CNVs, typically having  4 DNA copies
(12,13,32). While we have not analysed assays of this
nature in this study, qicPCR using the paralogue ratio
test (25) has been previously demonstrated to have suﬃ-
cient sensitivity to genotype complex CNVs (25,32). Given
this and the sensitivity of the data reported in this study, it
is possible that qicPCR will be suﬃciently sensitive to
allow the genotyping of more complex copy number poly-
morphisms, however further analysis will be required to
determine this. All assays performed in this study were
performed using the Sequenom Massarray genotyping
platform which is best suited to analysing multiplex
panels of 30–40 assays and consequently limited to analys-
ing  6 CNVs simultaneously. Given that qicPCR can
potentially be performed using any SNP genotyping
assay that generates a quantitative readout of the signal
intensity for each allele, it can be applied to currently
available array-based platforms and therefore oﬀers a
potential that could be used in very large-scale CNV geno-
typing studies.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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